Wasatch Advisors LP Buys New Shares in Pediatrix Medical Group, Inc. $MD

Wasatch Advisors LP purchased a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,050,524 shares of the company’s stock, valued at approximately $43,861,000. Wasatch Advisors LP owned 2.47% of Pediatrix Medical Group at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Louisiana State Employees Retirement System bought a new position in shares of Pediatrix Medical Group during the 1st quarter worth about $798,000. Ritholtz Wealth Management lifted its stake in shares of Pediatrix Medical Group by 42.1% in the first quarter. Ritholtz Wealth Management now owns 143,668 shares of the company’s stock valued at $3,073,000 after buying an additional 42,553 shares during the period. Evolve Private Wealth LLC grew its position in Pediatrix Medical Group by 12.7% during the first quarter. Evolve Private Wealth LLC now owns 33,115 shares of the company’s stock worth $708,000 after buying an additional 3,733 shares in the last quarter. Diversified Trust Co grew its position in Pediatrix Medical Group by 12.7% during the first quarter. Diversified Trust Co now owns 26,433 shares of the company’s stock worth $565,000 after buying an additional 2,982 shares in the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in Pediatrix Medical Group by 814.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock worth $12,713,000 after buying an additional 529,367 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.80% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Stock Up 2.0%

Shares of MD opened at $24.60 on Friday. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 11.94 and a beta of 0.69. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group, Inc. has a 12 month low of $11.84 and a 12 month high of $24.99. The company has a 50-day moving average price of $22.89 and a two-hundred day moving average price of $21.75.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The company had revenue of $476.20 million for the quarter, compared to analyst estimates of $465.83 million. During the same period in the prior year, the company posted $0.33 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Mizuho set a $24.00 price target on Pediatrix Medical Group in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday. UBS Group boosted their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Truist Financial upped their target price on Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, April 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $22.50.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.